Abstract 84P
Background
Macrophages represent the main infiltrating immune subset in most cancer types and tumor-associated macrophages (TAMs) sustain tumor growth, promote invasion and mediate immune suppression. Interestingly, a population of lipid-loaded macrophages has been recently identified in prostate cancer, colon cancer and melanoma. However, the mechanisms that drive lipid accumulation in macrophages and the functional impact of lipid-loading still need to be uncovered.
Methods
We profiled the cancer immune infiltrate in a murine model of melanoma and we performed bulk RNA sequencing of lipid-loaded macrophages to investigate pathways involved in lipid accumulation. We applied in vitro assays to dissect the interplay between macrophages and melanoma cells and we took advantage of immunofluorescence analysis to study the mechanisms responsible for lipid accumulation in tumor-conditioned macrophages.
Results
We confirmed that lipid accumulation is a feature of TAMs in melanoma and we observed that lipid-loaded macrophages express markers of immunosuppression, including arginase and PD-L1. Importantly, the abundance of lipid-loaded macrophages correlates with tumor size, suggesting their support to tumor progression. In vitro, cancer cells shift the polarization of macrophages toward a pro-tumoral state and augment their capability to accumulate lipid droplets when triggered with lipid species. In addition, autophagic flux resulted impaired in macrophages exposed to tumor cells, suggesting defective autophagy as a potential mechanism responsible for lipid accumulation. In the end, we observed that transcription factor EB (TFEB) is deregulated in tumor-conditioned macrophages, indicating a role of TFEB in promoting autophagy deficiency and lipid accumulation in TAMs.
Conclusions
Here we show that TAMs in melanoma accumulate lipids and acquire pro-tumorigenic and immunosuppressive features. Additionally, the inactivation of transcription factor EB promotes a defective autophagic machinery that could be relevant in lipid accumulation in TAMs. In this context, we believe that TFEB activation may prevent lipid accumulation thus potentially improving efficacy of current available immunotherapies and therefore representing a promising opportunity for cancer therapy.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Fondazione AIRC per la Ricerca sul Cancro.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract